Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Cerilliant
UBS
Mallinckrodt
Express Scripts
Colorcon
AstraZeneca
US Army
Teva

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,829,595

« Back to Dashboard

Which drugs does patent 7,829,595 protect, and when does it expire?

Patent 7,829,595 protects SENSIPAR and is included in one NDA.

This patent has thirty-four patent family members in twenty-five countries.
Summary for Patent: 7,829,595
Title:Rapid dissolution formulation of a calcium receptor-active compound
Abstract:The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.
Inventor(s): Lawrence; Glen Gary (Thousand Oaks, CA), Alvarez; Francisco J. (Newbury Park, CA), Lin; Hung-Ren H. (Oak Park, CA), Ju; Tzuchi R. (Vernon Hills, IL)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:10/937,870
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,829,595
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Use;

Drugs Protected by US Patent 7,829,595

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Amgen SENSIPAR cinacalcet hydrochloride TABLET;ORAL 021688-001 Mar 8, 2004 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA ➤ Try a Free Trial
Amgen SENSIPAR cinacalcet hydrochloride TABLET;ORAL 021688-002 Mar 8, 2004 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA ➤ Try a Free Trial
Amgen SENSIPAR cinacalcet hydrochloride TABLET;ORAL 021688-003 Mar 8, 2004 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,829,595

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,375,405 Rapid dissolution formulation of a calcium receptor-active compound ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,829,595

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 045637 ➤ Try a Free Trial
Australia 2004279318 ➤ Try a Free Trial
Brazil PI0414254 ➤ Try a Free Trial
Canada 2536487 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Cantor Fitzgerald
Citi
QuintilesIMS
Teva
Fish and Richardson
Cerilliant
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.